Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Juan Cueva, Laurence Gladieff et al.|The Lancet|2023Cited by 225
ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancersCristiana Sessa, Gabriele Calaminus, Dominik T. Schneider et al.|The Lancet Oncology|2020Cited by 119
Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre studyDavid L. Phelps, Sadaf Ghaem‐Maghami, Jane Borley et al.|British Journal of Cancer|2017Cited by 33
Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histologyNicole Pfarr, Albrecht Stenzinger, Silvia Darb‐Esfahani et al.|Genes Chromosomes and Cancer|2017Cited by 27
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPEMaria Otth, Elena Oltenau, Auke Beishuizen et al.|The Lancet Oncology|2022Cited by 10